Skip to content

Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 Diabetes

Enteroendocrine Cells in Healthy Individuals and Patients With Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03044860
Enrollment
24
Registered
2017-02-07
Start date
2011-03-31
Completion date
2012-06-30
Last updated
2017-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes

Brief summary

Investigation of the anatomical distribution of enteroendocrine cells by a systematic approach along the entire human intestinal tract in healthy individuals and patients with type 2 diabetes.

Detailed description

Enteroendocrine K and L cells are pivotal in regulating appetite and glucose homeostasis, but knowledge of their distribution in man is sparse and it is unknown whether alterations occur in type 2 diabetes. Twelve patients with type 2 diabetes and 12 age and BMI-matched healthy individuals underwent upper and lower double-balloon enteroscopy with mucosal biopsy retrieval from every \ 30 cm of the small intestine and specific locations in the large intestine. The investigators evaluated the distribution of enteroendocrine cells (using IHC staining for their specific hormonal products) and evaluated mRNA expression of the corresponding genes along the entire intestinal tract in patients with type 2 diabetes and in healthy individuals.

Interventions

PROCEDUREDouble-balloon enteroscopy (DBE) with biopsy retrieval

With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every \ 30 cm of the small intestine and specific locations in the large intestine

Sponsors

University Hospital, Gentofte, Copenhagen
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Type 2 diabetes patients * Diagnosis of type 2 diabetes (at least 3 months prior to study inclusion) * Treatment with diet counseling alone or combined with an glucose-lowering drugs: metformin or sulphonylurea * Caucasian ethnicity * Age \>25 and \<70 years * Normal hemoglobin * Negative for autoantibodies to glutamic acid decarboxylase (GAD-65) and islet cell autoantibodies (ICA). Healthy individuals * Fasting plasma glucose \<6.0 mM * Plasma glucose 2 hours after a 75 g-oral glucose tolerance test \<7.8 mM * Negative for GAD-65 antibodies and ICA * Caucasian ethnicity * Age \>25 and \<70 years * Normal hemoglobin

Exclusion criteria

Type 2 diabetes patients * Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase \>2 times normal value) * Treatment with dipeptidyl peptidase 4 inhibitors or medicine that could not be paused for 12 hours * Previous hysterectomy, appendectomy, cholecystectomy or caesarean * Sleep apnea * American Society of Anesthesiologists class \>3 * Allergy to soy protein or eggs * BMI \>35 kg/m2 or any other condition that would contraindicate propofol sedation or enteroscopy. Healthy individuals * Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase \>2 times normal value) * Liver disease (evaluated by alanine aminotransferase and/or aspartate aminotransferase \>2 times normal value) * Treatment with dipeptidyl peptidase 4 inhibitors or medicine that could not be paused for 12 hours * Previous hysterectomy, appendectomy, cholecystectomy or caesarean * Sleep apnea * American Society of Anesthesiologists class \>3 * Allergy to soy protein or eggs * BMI \>35 kg/m2 or any other condition that would contraindicate propofol sedation or enteroscopy * First-degree relative(s) with type 1 or type 2 diabetes.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of enteroendocrine cells (density and mRNA expression) in the intestinal tract.Cross-sectional study. Each participant went through two study days (upper and lower double-ballon enteroscopy, respectively)Using a double-balloon enteroscopy device, mucosal biopsies are obtained from the entire intestinal tract in 12 healthy individuals and 12 patients diagnosed with type 2 diabetes. The biopsies are analysed using immunohistochemistry (IHC) and mRNA expression analysis. Positively stained enteroendocrine cells (from IHC) are counted and divided by the epithelial area providing 'density' (cells/mm2). The data obtained from cell count and mRNA expression analysis present the variation in number of enteroendocrine cells (density) and the expression of hormonal products along the intestinal tract.
Evaluation of differences in enteroendocrine cells (density and mRNA expression) along the intestinal tract of healthy individuals compared with type 2 diabetes patients.Cross-sectional study. Each participant went through two study days (upper and lower double-ballon enteroscopy, respectively)Using a double-balloon enteroscopy device, mucosal biopsies are obtained from the entire intestinal tract in 12 healthy individuals and 12 patients diagnosed with type 2 diabetes. The biopsies are analysed using immunohistochemistry (IHC) and mRNA expression analysis. Positively stained enteroendocrine cells (from IHC) are counted and divided by the epithelial area providing 'density' (cells/mm2). Cell count (density) and mRNA expression data obtained from the healthy individuals and type 2 diabetes patietns are compared to evaluate potential differences between the two groups.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026